Some studies have raised the prospect of metformin use to suppress the initiation and recurrence of TSC-associated tumors, which would induce fewer side effects and have a lower cost than other mTOR inhibitors (Amin et al., 2019). Here, MTOR is linked to tuberous sclerosis.